Cuts deep.

Speaking of haters, here’s a propensity-matched NCDB analysis reporting patients receiving SBRT for inoperable non-small cell lung cancer from 2004-2016 (<1% of cohort) suffer significantly shorter median survival (47 months) compared with their operable counterparts (74 months). | Khorfan, Ann Thorac Surg 2020